Aptevo Therapeutics President, CEO Marvin White To Retire, Effective April 1, Transitioning To Executive Chair; COO Jeff Lamothe Appointed President, CEO

Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced executive leadership transitions to support the Company's continued execution, drive achievement of long-term strategic objectives, and next phase of growth.

Effective April 1, 2026, Marvin White, who has served as President and Chief Executive Officer since 2016, has chosen to retire from this position and assume the role of Executive Chair, where he will focus on cultivating strategic opportunities to help shape long-term success. Jeff Lamothe, currently Chief Operating Officer, will assume the role of President and Chief Executive Officer and will join Aptevo's Board of Directors. John E. Niederhuber, M.D., will transition from Chairman of the Board to Lead Independent Director. All three leaders have been part of Aptevo since the Company's inception in 2016, and the leadership changes reinforce continuity while supporting the Company's continued execution and future success.